A double-blind trial on the effects of atorvastatin on glycemic control inJapanese diabetic patients with hypercholesterolemia

Citation
A. Tanaka et al., A double-blind trial on the effects of atorvastatin on glycemic control inJapanese diabetic patients with hypercholesterolemia, CLIN CHIM A, 312(1-2), 2001, pp. 41-47
Citations number
14
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
CLINICA CHIMICA ACTA
ISSN journal
0009-8981 → ACNP
Volume
312
Issue
1-2
Year of publication
2001
Pages
41 - 47
Database
ISI
SICI code
0009-8981(200110)312:1-2<41:ADTOTE>2.0.ZU;2-8
Abstract
A double-blind, placebo-control led, parallel-group study was performed to determine whether atorvastatin, a new HMG-CoA reductase inhibitor, could ef fectively and safely reduce plasma LDL-cholesterol concentrations in Japane se patients with type-2 diabetes without influencing glycemic control. The subjects were patients with hypercholesterolemia (serum cholesterol concent ration;greater than or equal to 5.7 mmol/l (220 mg/dl)) and stable glycemic control. The fasting concentrations of hemoglobin A(1C) (HbA(1C)), fructos amine, and 1,5-anhydroglucitol (1,5-AG) were-measured as indices of glycemi c control, Plasma lipid concentrations and the safety of the drug were also examined. Forty eligible patients in two groups of 20 each were administer ed atorvastatin (10 mg/day) or placebo. Neither atorvastatin nor placebo ca used a significant change in HbA(1C), fructosainine, or 1,5-AG concentratio ns. Atorvastatin significantly reduced total cholesterol mad LDL-cholestero l concentrations from baseline by 29.7% (p < 0.0001) and 41.6% (1) < 0.0001 ), respectively. The incidence of clinical adverse events and that of abnor mal changes in laboratory test values did not differ between the two groups . In this trial, atorvastatin effectively and safely reduced LDL-cholestero l concentrations in diabetic patients with hypercholesterolemia without inf luencing glycemic control. These findings are clinically important because there are many diabetic patients with hypercholesterolemia and such patient s have a high risk of developing arteriosclerotic disease. (C) 2001 Elsevie r Science B.V. All rights reserved.